Stan­ford stem cell pi­o­neer nets $194M from Gilead-Forty Sev­en buy­out

6 years ago
People
Deals

A biotech tests Wall Street's roiled wa­ters and comes away with a $75M IPO haul

6 years ago
R&D

Dis­ap­point­ing PhI­II re­sults dash As­traZeneca's hopes of re­viv­ing a tar­nished can­cer drug through Lyn­parza com­bo

6 years ago
R&D

As the coro­n­avirus pan­dem­ic con­tin­ues to rat­tle the world, bio­phar­ma braces for a few new shocks to the sys­tem

6 years ago
Coronavirus

Har­bour Bio­Med nets $75M in Se­ries B+ as first glob­al tri­al gets un­der­way

6 years ago
Financing

Back to the draw­ing board for triple-neg­a­tive breast can­cer tar­gets, re­searchers pro­pose new com­bo ap­proach

6 years ago
Discovery

Bris­tol My­ers scores new FDA nod for Op­di­vo/Yer­voy com­bo; US Army wants Gilead­'s po­ten­tial Covid-19 drug for in­fect­ed ...

6 years ago
News Briefing

A JP Mor­gan promise, a last-minute bid and the coro­n­avirus stock mar­ket — how Gilead’s Daniel O’Day nabbed ...

6 years ago
Deals
R&D

Is HKEX ready to re­turn to biotech busi­ness? In­no­Care tests wa­ters with hopes to fetch $257M in IPO

6 years ago
Financing
China

With WuXi and Al­ny­lam in tow, Vir en­lists NIH as it tests var­i­ous tools to fight the coro­n­avirus scourge

6 years ago
R&D
Coronavirus

An­a­lysts start to sort out which bio­phar­ma com­pa­nies’ R&D plans are most threat­ened by a pan­dem­ic

6 years ago
R&D
Coronavirus

In search of a Ku­ur: Cell Med­ica re­brands and re­groups, tak­ing a new name, a new CEO and new mon­ey

6 years ago
R&D

FDA drafts guid­ance on al­ter­nate elec­tron­ic for­mats, an­nounces sup­port for new da­ta stan­dards

6 years ago
FDA+

The glob­al top 50 bio­phar­ma com­pa­nies — End­points News style

6 years ago
R&D

Sil­ver­back Ther­a­peu­tics gets $78M boost to 'recon­cep­tu­al­ize' an­ti­body-drug con­ju­gates

6 years ago
Financing
Startups

Af­ter hit­ting big in mul­ti­ple myelo­ma, J&J, Gen­mab now have a new 'break­through' in NSCLC to boast about

6 years ago
FDA+

Intar­ci­a's speed bump at the FDA turns in­to a road­block, as reg­u­la­tors once again turn thumbs down on di­a­betes ...

6 years ago
R&D
Pharma

Bio­gen out­break now tied to 70 cas­es of coro­n­avirus as state to­tal more than dou­bles in 1 day

6 years ago
Coronavirus

Coro­n­avirus up­date: Eli Lil­ly staffer tests pos­i­tive, FDA post­pones in­spec­tions and AACR is can­celed as out­break ...

6 years ago
Coronavirus

Sy­neos up for sale — re­port; Takeda's Nin­laro fails PhI­II in mul­ti­ple myelo­ma; EMA braces for drug short­age

6 years ago
News Briefing

To arm the im­mune sys­tem for sus­tained at­tack against HIV, NIH sci­en­tists take to vi­ral vec­tors

6 years ago
R&D
Cell/Gene Tx

J&J's fa­vorite CAR-T de­vel­op­er, cur­rent­ly owned by a Chi­nese CRO, is lay­ing the ground­work for US IPO

6 years ago
Financing
Cell/Gene Tx

Which top-lev­el Bio­gen ex­ec has test­ed pos­i­tive for coro­n­avirus? WSJ nar­rows the lot­tery to 4, in­clud­ing the CEO

6 years ago
Coronavirus

Is­rael’s Arkin Hold­ings launch­es sec­ond biotech fund, worth $140 mil­lion

6 years ago
Financing
First page Previous page 860861862863864865866 Next page Last page
A service from the Financial Times